Veeva

Veeva Systems - Cloud-based Software for the Global Life Sciences Industry

Veeva is a leading global provider of industry-specific, cloud-based software solutions for the life sciences industry. Our solutions enable pharmaceutical and other life sciences companies to realize the benefits of modern cloud-based architectures and mobile applications for their most critical business functions, without compromising industry-specific functionality or regulatory compliance.

Latest News

February 27, 2018 Veeva Announces Fourth Quarter and Fiscal Year 2018 Results
Fiscal Year 2018 Total Revenues of $685.6M, up 26% Year-over-year;
Q4 Total Revenues of $184.9M, up 23% Year-over-year Fiscal Year 2018 Subscription Services Revenues of $554.4M, up 28% Year-over-year; Q4 Subscription Services Revenues of $150.9M, up 26% Year-over-year Veeva Systems Inc. (NYSE: VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its fiscal fourth quarter and full year ended January 31, 2018 . “The fourth quarter was a strong finish to another great year for Veeva,” said CEO Peter Gassner. “We have a proven track record of increasing value for customers through innovation and are in the early stages of more major growth opportunities than at any point in our history. This combined with our disciplined execution sets us up for continued strong growth well into the future.” Fiscal 2018 Fourth Quarter Results: Revenues: Total revenues for the fourth quarter were $184.9 million, up from...
December 5, 2017 Veeva Announces Fiscal 2018 Third Quarter Results
Total Revenues of $176.1M, up 23% Year-Over-Year Subscription Services Revenues of $141.9M, up 25% Year-Over-Year Veeva Systems Inc. (NYSE: VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its fiscal third quarter ended October 31, 2017. “Veeva delivered another strong quarter with results above our guidance,” said CEO Peter Gassner . “We executed well across all product areas and geographies and went the extra mile for customer success. We also announced a new product line, Veeva Vault Safety, to help our customers become more efficient, effective and compliant when managing drug safety." Fiscal 2018 Third Quarter Results: Revenues : Total revenues for the third quarter were $176.1 million , up from $142 .8 million one year ago, an increase of 23% year-over-year. Subscription services revenues for the third quarter were $141.9 million , up from $113.6 million one year ago, an increase of 25% year-over-year....
September 21, 2017 Industry Survey Reveals Clinical Data Management Delays Are Slowing Trial Completion
83% of life sciences organizations release the clinical database after first patient, first visit, which is associated with downstream delays of up to a month in key data management activities One of the largest, most in-depth surveys of clinical data management professionals shows that the time it takes companies to design and release clinical study databases is having a negative impact on conducting and completing trials. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170921005426/en/ (Graphic: Business Wire) According to the 2017 eClinical Landscape Study from Tufts Center for the Study of Drug Development , it takes companies an average of 68 days to build and release a clinical study database. Delays in releasing the study database are associated with an increase of nearly a month downstream for other data management processes such as patient data entry and time to lock the database at the end of the study....

Investor Contact

Rick Lund
Investor Relations Director
Email: ir@veeva.com
Phone: 1 (925) 271-9816

Email Alerts

Email *
Mailing Lists *

 
Enter the code shown above.